2017-02-09,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 On February 13
2017-01-06,Aradigm To Present At 9th Annual Biotech Showcase Conference On January 9
2016-12-01,Dow Trades Above Record Close Despite Pull From Tech Selloff
2016-12-01,Bank Stocks Boost Dow, Crude Rallies for Day Two
2016-12-01,Aradigm Announces Top-Line Results From Two Phase 3 Studies Evaluating Pulmaquin For The Chronic Treatment Of Non-Cystic Fibrosis Bronchiectasis Patients With Lung Infections With Pseudomonas Aeruginosa
2016-11-10,Aradigm To Present At The Stifel 2016 Healthcare Conference On November 16
2016-11-09,Aradigm Announces Third Quarter 2016 Financial Results
2016-10-18,Multi-million Dollar DTRA Funding For Biodefense Research With Aradigm's Inhaled Ciprofloxacin
2016-10-07,Aradigm Announces Australian Research Council Funding To Develop Nanotechnologies Targeting Bacterial And Fungal Biofilms
2016-09-22,Aradigm Announces Last Patient Dosing Visit In ORBIT-3 And ORBIT-4 Phase 3 Studies Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis Patients
2016-09-21,Aradigm To Host Analyst Meeting And Webcast On September 26 In New York City
2016-09-20,Aradigm To Present At The Ladenburg Thalmann 2016 Healthcare Conference On September 27
2016-08-10,Aradigm Announces Second Quarter 2016 Financial Results
2016-05-11,Two Presentations On Aradigm's Inhaled Liposomal Ciprofloxacin Programs At The American Thoracic Society 2016 International Conference
2016-05-10,Aradigm Announces First Quarter 2016 Financial Results
2016-04-26,Aradigm Corporation Announces First Closing Of Private Placement Offering Of $23 Million Senior Convertible Notes Due 2021
2016-04-22,Aradigm Corporation Prices Private Placement Of Senior Notes
2016-03-17,Aradigm Announces Decision For Centralized Review Of Pulmaquin By The European Medicines Agency
2016-03-15,Aradigm Announces Fourth Quarter 2015 And Full Year Financial Results
2016-02-02,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 On February 8
2016-01-05,Aradigm To Host Corporate Update Conference Call On January 6
2015-11-11,Aradigm Announces Third Quarter 2015 Financial Results
2015-10-13,Aradigm Corporation Completes Enrollment In The Second Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
2015-09-23,Aradigm To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29
2015-09-22,Aradigm Corporation Completes Enrollment In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
2015-09-10,Results From Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin To Be Presented At ICAAC/ICC 2015
2015-08-20,3 Stocks Pushing The Drugs Industry Lower
2015-08-13,Aradigm Announces Second Quarter 2015 Financial Results
2015-08-12,3 Stocks Pushing The Drugs Industry Lower
2015-08-12,3 Stocks Pushing The Health Care Sector Lower
2015-08-06,3 Stocks Pushing The Health Care Sector Lower
2015-08-06,3 Stocks Pushing The Drugs Industry Lower
2015-06-08,Ratings Changes Today
2015-05-14,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of ARADIGM CORPORATION
2015-05-12,Results From Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin To Be Presented At The American Thoracic Society 2015 International Conference
2015-05-11,Aradigm Announces First Quarter 2015 Financial Results
2015-04-21,Aradigm Announces Appointment Of Dr. Robert A. Reed As Vice President, Regulatory (Chemistry, Manufacturing And Controls) And Quality
2015-04-16,Aradigm To Host Key Opinion Leader Breakfast And Webcast On April 23 In New York City
2015-03-20,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Aradigm Corporation -- ARDM
2015-03-17,Aradigm Announces Fourth Quarter 2014 And Full Year Financial Results
2015-02-04,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2015 On February 10
2015-01-20,Aradigm (ARDM) Upgraded From Sell to Hold
2015-01-16,Ratings Changes Today
2015-01-14,Aradigm Granted Key Composition Of Matter Patents For Pulmaquin In Europe And Australia
2015-01-08,Aradigm To Present At Biotech Showcase 2015 On January 14
2014-11-12,Aradigm To Present At The Stifel Healthcare Conference 2014
2014-11-07,Aradigm Announces Third Quarter 2014 Financial Results
2014-10-31,Aradigm (ARDM) Downgraded From Hold to Sell
2014-10-30,Ratings Changes Today
2014-09-22,Aradigm (ARDM) Upgraded From Sell to Hold
2014-09-19,Ratings Changes Today
2014-09-04,FDA Grants Fast Track Designation To Aradigmâ€™s Pulmaquin For Non-Cystic Fibrosis Bronchiectasis
2014-08-20,3 Drugs Stocks Pushing The Industry Higher
2014-08-14,3 Drugs Stocks Pushing The Industry Higher
2014-08-07,Aradigm Announces Second Quarter 2014 Financial Results
2014-08-06,Aradigm To Host Analyst Meeting And Webcast On August 12 In New York City
2014-06-25,Aradigm To Host Corporate Update Conference Call On June 26
2014-06-23,Aradigm Corporation Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
2014-06-03,Aradigm Receives $5 Million Milestone For Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis
2014-05-20,FDA Grants QIDP Designation To Aradigm&#8217;s Inhaled Antibiotic
2014-05-14,Aradigm Announces First Quarter 2014 Financial Results
2014-04-30,Aradigm Corporation Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
2014-04-15,Results From Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm&#8217;s Liposomal Ciprofloxacin To Be Presented At The American Thoracic Society 2014 International Conference
2014-03-13,Aradigm Announces Fourth Quarter 2013 And Full Year Financial Results
2014-02-04,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference 2014 On February 11
2014-01-08,Aradigm To Present At Biotech Showcase 2014 On January 14
2013-11-19,Aradigm Announces Appointment Of Dr. Juergen Froehlich As Chief Medical Officer
2013-10-28,Aradigm Announces Third Quarter 2013 Financial Results
2013-09-18,Aradigm Announces Changes To Its Board Of Directors
2013-09-16,Sigma-Tau PharmaSource, Inc. And Aradigm Corporation Sign Manufacturing Agreement For The Clinical And Commercial Supply Of Pulmaquin
2013-09-09,Aradigm To Present At The Stifel Nicolaus 2013 Healthcare Conference
2013-08-28,Grifols And Aradigm Corporation Complete The Closing Of Worldwide Licensing Agreement To Develop And Commercialize Pulmaquin&#174;
2013-08-08,Aradigm Announces Second Quarter 2013 Financial Results
2013-08-07,Aradigm Awarded NIH Grant To Investigate New Methods Of Diagnoses Of Aspirations Of Gastrointestinal Contents Into The Respiratory Tract With Scientists At UC San Francisco
2013-08-01,Aradigm Awarded NIH Grant To Investigate The Treatment Of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections With Pulmaquin And Lipoquin
2013-07-16,Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. To Develop And Commercialize Pulmaquin
2013-03-26,Aradigm Announces Fourth Quarter 2012 And Full Year Financial Results
2013-02-06,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference 2013 On February 12
2013-01-03,Aradigm To Present At Biotech Showcase 2013 On January 9
2012-11-19,UK Scientists Report On Efficacy Of Aradigm&#8217;s Lipoquin&#8482; Against Pneumonic Plague
2012-11-08,Aradigm Announces Third Quarter 2012 Financial Results
2012-10-16,Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect Of Aradigm&#8217;s Inhaled Liposomal Ciprofloxacin
2012-09-20,UK Scientists Report Successful Testing Of Aradigm&#8217;s Inhaled Liposomal Ciprofloxacin In Q Fever
2012-09-18,New U.S. Composition Of Matter Patent For Aradigm&#8217;s Pulmaquin&#8482; And Lipoquin&#8482; Provides Protection Until 2031
2012-09-05,Aradigm Patent Protection For Smoking Cessation Is Extended With Issuance Of A Method Of Treatment Patent
2012-08-30,Aradigm To Participate In FDA Workshop On Non-Cystic Fibrosis Bronchiectasis
2012-08-29,Aradigm To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-09,Aradigm Announces Second Quarter 2012 Financial Results
2012-03-27,Aradigm Announces Fourth Quarter 2011 And Full Year Financial Results
2012-03-12,Aradigm Receives U.S. FDA Clearance For Phase 3 Clinical Trial Of Pulmaquin&#8482; In Patients With Non-Cystic Fibrosis Bronchiectasis
2012-02-21,US Patent Protection For Pulmaquin&#8482; Is Extended With Issuance Of A Composition Of Matter Patent
2012-02-08,Aradigm To Present At The Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference 2012 On February 13
2012-01-05,Aradigm To Present At Biotech Showcase 2012 On January 9
2011-12-07,Aradigm Selects Pulmaquin&#8482; For Phase 3 Development And Announces Issuance Of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
2011-11-10,Aradigm Announces Third Quarter 2011 Financial Results
2011-10-20,Aradigm To Present At The 10th Annual BIO Investor Forum On October 26
2011-09-21,Aradigm Presents Additional Analyses Of The Clinical Results From ORBIT-1 And ORBIT-2 Trials Of Inhaled Ciprofloxacin At The 2011 European Respiratory Society (ERS) Annual Congress
2011-09-07,Aradigm To Present At Rodman &amp; Renshaw Annual Global Investment Conference
2011-08-09,Aradigm Announces Second Quarter 2011 Financial Results
2011-07-06,Aradigm Announces Private Placement For $4.75 Million
2011-06-22,Aradigm Enters $8.5 Million Royalty Financing Agreement With PBS Capital Management LLC
2011-06-16,Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
2011-06-06,Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis
2011-05-12,Aradigm Announces First Quarter 2011 Financial Results
2011-05-03,Aradigm To Present Additional ORBIT-2 Clinical Trial Results At Respiratory Drug Delivery Europe 2011 Conference
2011-03-24,Aradigm Announces Fourth Quarter 2010 And Full Year Financial Results
2011-03-22,Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections In Bronchiectasis
2011-03-10,Aradigm To Present At ROTH Capital Partners 23rd Annual OC Growth Stock Conference
2011-02-10,Aradigm To Present At The 13th Annual Biotechnology Industry Organization (BIO) CEO &amp; Investor Conference
2011-01-11,SUMAVEL DosePro Receives Marketing Approval In Germany And The United Kingdom
2011-01-06,Aradigm To Report Expanded Results From Successful Six-Month Phase 2b Bronchiectasis Study At Biotech Showcase 2011
2010-12-07,SUMAVEL DosePro Is Granted First European Approval
2010-11-11,Aradigm Announces Third Quarter 2010 Financial Results
2010-11-04,Aradigm Appoints Tamar Howson To Board Of Directors
2010-11-02,Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 For Inhaled Liposomal Ciprofloxacin Program
2010-10-20,Aradigm Reports Successful Phase 2b Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
2010-10-04,Aradigm To Present At The 9th Annual BIO Investor Forum On October 6
2010-09-30,Aradigm CEO Igor Gonda To Be Featured Guest Interview On StockGoodies.com Radio On September 30
2010-09-20,Aradigm Closes Equity For Debt Transaction With Novo Nordisk A/S
2010-09-17,Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations At The 2010 European Respiratory Society (ERS) Annual Congress
2010-08-12,Aradigm Announces Second Quarter 2010 Financial Results
2010-08-02,Aradigm Announces Equity For Debt Transaction With Novo Nordisk
2010-06-21,Aradigm Announces Private Placement For $5 Million
2010-05-17,Aradigm Presents At The 2010 International Conference Of The American Thoracic Society
2010-05-13,Aradigm Announces First Quarter 2010 Financial Results
2010-05-05,Aradigm Receives FDA Clearance For Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Pediatric Patients With Cystic Fibrosis
2010-03-25,Aradigm Completes Enrollment And Doses Last Patient In Long Term Phase 2 Study Of A Novel Inhaled Ciprofloxacin Formulation For The Management Of Respiratory Infections In Bronchiectasis
2010-02-23,Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis Patients
2010-02-04,Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale Of SUMAVEL* DosePro*
2005-07-15,MannKind's Work Is Never Done
2005-06-10,Exubera-nce in the Insulin Market
2004-12-14,Pressure Builds in PIPEs
2004-09-29,Health Stocks in Motion
2001-07-17,Drug Delay Has Inhale Gasping and a Rival Catching Up
,
